GeoVax Partners With French Firm
July 25, 2008
On Thursday, Atlanta-based GeoVax Labs Inc. announced a new partnering agreement under which a component of its candidate HIV vaccine will be manufactured by the French firm Vivalis. GeoVax has reported progress toward Phase II preventive clinical human trials of its vaccine and plans to move into therapeutic human trials this fall, said Robert McNally, its president and CEO. The Phase II trial will be conducted by the National Institutes of Health with the support of the HIV Vaccine Trials Network. It will involve 225 healthy volunteers from the United States and South America.
07.25.2008; Bill Hendrick
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.